219 related articles for article (PubMed ID: 33929501)
1. LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα.
Kohrogi K; Hino S; Sakamoto A; Anan K; Takase R; Araki H; Hino Y; Araki K; Sato T; Nakamura K; Nakao M
Blood Adv; 2021 May; 5(9):2305-2318. PubMed ID: 33929501
[TBL] [Abstract][Full Text] [Related]
2. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.
Wagner K; Zhang P; Rosenbauer F; Drescher B; Kobayashi S; Radomska HS; Kutok JL; Gilliland DG; Krauter J; Tenen DG
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6338-43. PubMed ID: 16606850
[TBL] [Abstract][Full Text] [Related]
3. LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.
Tatsumi G; Kawahara M; Yamamoto R; Hishizawa M; Kito K; Suzuki T; Takaori-Kondo A; Andoh A
Leukemia; 2020 Mar; 34(3):746-758. PubMed ID: 31676828
[TBL] [Abstract][Full Text] [Related]
4.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
5. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
[TBL] [Abstract][Full Text] [Related]
6. Histone demethylase LSD1-mediated repression of GATA-2 is critical for erythroid differentiation.
Guo Y; Fu X; Jin Y; Sun J; Liu Y; Huo B; Li X; Hu X
Drug Des Devel Ther; 2015; 9():3153-62. PubMed ID: 26124638
[TBL] [Abstract][Full Text] [Related]
7. Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia.
Leonards K; Almosailleakh M; Tauchmann S; Bagger FO; Thirant C; Juge S; Bock T; Méreau H; Bezerra MF; Tzankov A; Ivanek R; Losson R; Peters AHFM; Mercher T; Schwaller J
Nat Commun; 2020 Jun; 11(1):2807. PubMed ID: 32533074
[TBL] [Abstract][Full Text] [Related]
8. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
Fagnan A; Bagger FO; Piqué-Borràs MR; Ignacimouttou C; Caulier A; Lopez CK; Robert E; Uzan B; Gelsi-Boyer V; Aid Z; Thirant C; Moll U; Tauchmann S; Kurtovic-Kozaric A; Maciejewski J; Dierks C; Spinelli O; Salmoiraghi S; Pabst T; Shimoda K; Deleuze V; Lapillonne H; Sweeney C; De Mas V; Leite B; Kadri Z; Malinge S; de Botton S; Micol JB; Kile B; Carmichael CL; Iacobucci I; Mullighan CG; Carroll M; Valent P; Bernard OA; Delabesse E; Vyas P; Birnbaum D; Anguita E; Garçon L; Soler E; Schwaller J; Mercher T
Blood; 2020 Aug; 136(6):698-714. PubMed ID: 32350520
[TBL] [Abstract][Full Text] [Related]
9. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
[TBL] [Abstract][Full Text] [Related]
10. GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia.
Burda P; Vargova J; Curik N; Salek C; Papadopoulos GL; Strouboulis J; Stopka T
PLoS One; 2016; 11(3):e0152234. PubMed ID: 27010793
[TBL] [Abstract][Full Text] [Related]
11. C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor.
Di Genua C; Valletta S; Buono M; Stoilova B; Sweeney C; Rodriguez-Meira A; Grover A; Drissen R; Meng Y; Beveridge R; Aboukhalil Z; Karamitros D; Belderbos ME; Bystrykh L; Thongjuea S; Vyas P; Nerlov C
Cancer Cell; 2020 May; 37(5):690-704.e8. PubMed ID: 32330454
[TBL] [Abstract][Full Text] [Related]
12. Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU.1.
Fujiwara T; Sasaki K; Saito K; Hatta S; Ichikawa S; Kobayashi M; Okitsu Y; Fukuhara N; Onishi Y; Harigae H
Biochem Biophys Res Commun; 2017 Apr; 485(2):380-387. PubMed ID: 28216155
[TBL] [Abstract][Full Text] [Related]
13. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc.
Nagasaka M; Tsuzuki K; Ozeki Y; Tokugawa M; Ohoka N; Inoue Y; Hayashi H
Biol Pharm Bull; 2019; 42(3):481-488. PubMed ID: 30828079
[TBL] [Abstract][Full Text] [Related]
14. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
[TBL] [Abstract][Full Text] [Related]
15. Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia.
Magliulo D; Bernardi R; Messina S
Front Oncol; 2018; 8():255. PubMed ID: 30073149
[TBL] [Abstract][Full Text] [Related]
16. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
[TBL] [Abstract][Full Text] [Related]
17. The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.
Shimamoto T; Ohyashiki K; Ohyashiki JH; Kawakubo K; Fujimura T; Iwama H; Nakazawa S; Toyama K
Blood; 1995 Oct; 86(8):3173-80. PubMed ID: 7579412
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.
Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB
Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567
[TBL] [Abstract][Full Text] [Related]
20. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation.
He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H
Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
